Cytokinetics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Cytokinetics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. 

CEO
Robert I. Blum
CEORobert I. Blum
Employees
673
Employees673
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
1997
Founded1997
Employees
673
Employees673

CYTK Key Statistics

Market cap
7.88B
Market cap7.88B
Price-Earnings ratio
-9.79
Price-Earnings ratio-9.79
Dividend yield
Dividend yield
Average volume
1.71M
Average volume1.71M
High today
$64.50
High today$64.50
Low today
$59.55
Low today$59.55
Open price
$59.59
Open price$59.59
Volume
2.72M
Volume2.72M
52 Week high
$70.98
52 Week high$70.98
52 Week low
$29.31
52 Week low$29.31

Stock Snapshot

With a market cap of 7.88B, Cytokinetics(CYTK) trades at $64.50. The stock has a price-to-earnings ratio of -9.79.

During the trading session on 2026-05-01, Cytokinetics(CYTK) shares reached a daily high of $64.50 and a low of $59.55. At a current price of $64.50, the stock is +8.3% higher than the low and still 0.0% under the high.

Trading volume for Cytokinetics(CYTK) stock has reached 2.72M, versus its average volume of 1.71M.

Over the past 52 weeks, Cytokinetics(CYTK) stock has traded between a high of $70.98 and a low of $29.31.

Over the past 52 weeks, Cytokinetics(CYTK) stock has traded between a high of $70.98 and a low of $29.31.

CYTK News

TipRanks 2h
Top Cytokinetics Executive Makes Major Move With Insider Stock Sale

New insider activity at Cytokinetics ( (CYTK) ) has taken place on April 30, 2026. Unlock hedge fund-level data and powerful investing tools for smarter, sharp...

Investing.com 1d
Cytokinetics president & CEO Robert Blum sells $447k in shares - Investing.com

...

Cytokinetics president & CEO Robert Blum sells $447k in shares - Investing.com
Simply Wall St 7d
Is It Too Late To Consider Cytokinetics After Its 62% One-Year Surge?

Investors may be wondering whether Cytokinetics at around US$65.48 is still offering value, or if most of the upside is already reflected in the price. The sto...

Is It Too Late To Consider Cytokinetics After Its 62% One-Year Surge?

Analyst ratings

86%

of 22 ratings
Buy
86.4%
Hold
13.6%
Sell
0%

People also own

Based on the portfolios of people who own CYTK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.